Floatz logo

Repotrectinib

Invasive Lobular Breast Carcinoma

M.D. Anderson Cancer CenterSmall moleculePhase 2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Invasive Lobular Breast Carcinoma cohort.

Asset / SponsorPhaseRating
FULVESTRANT
M.D. Anderson Cancer Center
Phase 3BB
Arimidex
Alliance for Clinical Trials in Oncology
Phase 3B
FES F-18
Asan Medical Center
Phase 2B
FLUDEOXYGLUCOSE
Randy Yeh
Phase 2CCC
Neratinib
Vanderbilt-Ingram Cancer Center
Phase 2CCC

View all 21 →

Same molecule, other indications

Repotrectinib is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
hormone receptor-positive breast cancerDormant
CCC
Indicative ·
52 / 100
View asset →
ROS1 Gene RearrangementDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →